ArticleThe Laryngoscope2025
Sinonasal Intervention Reduces the Need for Pressure Equalization Tube Placement in Atopic Adults.
Article in The Laryngoscope, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sinonasal Intervention Reduces the Need for Pressure Equalization Tube Placement in Atopic Adults.The Laryngoscope · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine the impact of management of upper airway atopic disease on middle ear and eustachian tube function in adults.
methodsThe TriNetX Research Network was queried to construct cohorts of adult patients with atopic disorders of the upper airway (defined by ICD-10 codes for asthma, allergic rhinitis, and chronic rhinosinusitis with nasal polyposis) with concurrent eustachian tube dysfunction (ETD) undergoing medical or surgical intervention for their atopic disease, including monoclonal antibody (mAb) therapy (e.g., dupilumab, mepolizumab, omalizumab), topical nasal steroid spray (fluticasone propionate), functional endoscopic sinus surgery (FESS), septoplasty with inferior turbinate submucosal resection (BITSMR), and allergy immunotherapy. The primary measured outcome was the difference in the rate of pressure equalization tube (PET) placement before and after each intervention.
resultsFESS demonstrated an absolute risk reduction (ARR) of 10.0% (p < 0.05, 95% confidence interval [CI] 8.9%-11.1%), septoplasty/BITSMR 7.5% (p < 0.05, 95% CI 6.3%-8.7%), mAb 5.5% (p < 0.05, 95% CI 4.1%-6.8%), nasal steroid spray (fluticasone proprionate) 0.9% (p < 0.05, 95% CI 0.8%-1.0%), and allergy immunotherapy 2.4% (p < 0.05, 95% CI 1.5%-3.2%). Individually, the three mAb-dupilumab, mepolizumab, and omalizumab-exhibited ARR of 6.5% (p < 0.05%, 95% CI 4.8%-8.3%), 6.8% (p < 0.05, 95% CI 2.6%-11.0%), and 3.4% (p < 0.05, 95% CI 1.4%-5.4%), respectively, without significant differences in rates of PET placement among the three (p = 0.18).
conclusionManagement of upper airway atopic disorders via both medical and surgical intervention is associated with improvement in middle function as measured by the need for PET placement. LEVEL OF EVIDENCE: 3:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.